X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

COVID Jab Partner SII Stalls Output Due To 200M Unused Doses

Content Team by Content Team
25th April 2022
in News
DCGI nod to Serum-Oxford covid-19 vaccine for phase 2, 3 clinical trials in India

As worldwide demand dwindles, around 200 million doses of COVID-19 vaccine are rusting away in the world’s largest vaccine manufacturer’s warehouses.

As per Bloomberg, Serum Institute of India (SII) CEO Adar Poonawalla revealed at the India Economic Conclave that they had ceased producing fresh COVID-19 vaccine doses in December. According to him, the company now has a reserve of 200 million medicines. He has even offered free donations to anyone who wants them, Poonawalla said, raising concerns over potential waste.

SII’s condition reflects diminishing demand as the global sense of desperation for vaccination seems to be fading. Manufacturers like SII, which hastened to expand capacity in the face of an initial scarcity, are now bearing the brunt of the slowdown.

The impetus of the past that took us so far is lost, says Adar. 

According to the chief executive, the poor uptake is due to rising vaccine weariness among the public as well as the Indian government’s inability to act on authorizations for shorter dose periods and for young kids.

Demand for COVID vaccines has tailed off considerably since the impression is that omicron is less likely to lead to serious infection, and the vaccines aren’t doing a great job at infection prevention while still providing substantial security against severe illness, Eurasia Group’s Scott Rosenstein told Bloomberg independently. SII assists AstraZeneca in the development of Covishield, a shot developed in collaboration with Oxford University. It’s a key provider for the worldwide COVAX effort, which aims to make COVID vaccinations more broadly accessible. Because it has a lower temperature requirement than mRNA shots from Pfizer-BioNTech and Moderna, the AZ shot was originally the principal form of vaccine given to middle-and low-income countries.

However, poorer countries are increasingly refusing SII’s AZ injection, as per Reuters. A representative for Gavi, which helped start COVAX, told the news wire that a limited shelf life was listed as a factor. As per Reuters, throughout the six months from April to September, those countries only sought roughly half a million Covishield dosages and around 16 million doses of the dual Vaxzevria injectable made in Europe. SII is also partnering with Novavax on a recombinant protein vaccine which will be licenced for use in India as an emergency vaccination.

The downturn in COVID revenues isn’t limited to SII and AstraZeneca. Due to a considerable decline in demand, Johnson & Johnson has also stopped estimating income for their single-shot alternative. The J&J shot earned $457 million in the first quarter, significantly less than the $785 million predicted by Wall Street. According to Cantor Fitzgerald analysts, Pfizer and BioNTech’s Comirnaty, the world’s finest COVID injectable, may underperform in the first quarter. After looking into distribution figures, the team estimated that Comirnaty’s sales in the United States for the first three months of the year would likely be under $2 billion. In early May, Pfizer will publish its first-quarter earnings.

Previous Post

Sanofi Begins Work On €400 Million Singapore Future Facility

Next Post

FDA clears Insulet's next-generation Omnipod 5 wearable insulin delivery pump

Related Posts

Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Drug Development

Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

21st March 2025
Next Post
FDA clears Insulet's next-generation Omnipod 5 wearable insulin delivery pump

FDA clears Insulet's next-generation Omnipod 5 wearable insulin delivery pump

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In